CDI

439.8

-0.72%↓

KESKOB.FI

19.2

-0.16%↓

SZU

10

+0.1%↑

AGRB

11.2

0%↓

KOF

31.75

+1.28%↑

CDI

439.8

-0.72%↓

KESKOB.FI

19.2

-0.16%↓

SZU

10

+0.1%↑

AGRB

11.2

0%↓

KOF

31.75

+1.28%↑

CDI

439.8

-0.72%↓

KESKOB.FI

19.2

-0.16%↓

SZU

10

+0.1%↑

AGRB

11.2

0%↓

KOF

31.75

+1.28%↑

CDI

439.8

-0.72%↓

KESKOB.FI

19.2

-0.16%↓

SZU

10

+0.1%↑

AGRB

11.2

0%↓

KOF

31.75

+1.28%↑

CDI

439.8

-0.72%↓

KESKOB.FI

19.2

-0.16%↓

SZU

10

+0.1%↑

AGRB

11.2

0%↓

KOF

31.75

+1.28%↑

Search

Wendel SA.

Cerrado

SectorConsumo defensivo

82.05 0.49

Resumen

Variación precio

24h

Actual

Mínimo

81.45

Máximo

82.4

Métricas clave

By Trading Economics

Ingresos

-90M

Ventas

4.1B

Rentabilidad por dividendo

5.03

Margen de beneficio

-2.222

Empleados

92,426

EBITDA

904M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+36.16% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

5.03%

3.32%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

3.9B

Apertura anterior

81.56

Cierre anterior

82.05

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

70 / 150 Clasificación en Consumer defensive

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Wendel SA. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 21:42 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 ago 2025, 21:21 UTC

Ganancias
Principales Movimientos del Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 ago 2025, 23:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 ago 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 ago 2025, 23:28 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 ago 2025, 23:28 UTC

Charlas de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 ago 2025, 21:30 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 21:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 ago 2025, 21:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 20:25 UTC

Charlas de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss $938M >RIG

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss/Shr $1.06 >RIG

4 ago 2025, 20:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 ago 2025, 20:15 UTC

Ganancias

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 ago 2025, 20:13 UTC

Ganancias

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 ago 2025, 20:09 UTC

Ganancias

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 ago 2025, 20:06 UTC

Ganancias

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 ago 2025, 19:41 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 ago 2025, 19:28 UTC

Charlas de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 ago 2025, 19:07 UTC

Charlas de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 ago 2025, 18:27 UTC

Charlas de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparación entre iguales

Cambio de precio

Wendel SA. Esperado

Precio Objetivo

By TipRanks

36.16% repunte

Estimación a 12 meses

Media 109 EUR  36.16%

Máximo 118 EUR

Mínimo 94 EUR

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Wendel SA. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

87.05 / 87.65Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

70 / 150 Clasificación en Consumo defensivo

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Wendel SA.

Wendel is a private equity firm specializing in equity financing in middle markets and later stages through leveraged buy-out and transactions and acquisitions. It invests in both listed and non-listed companies. The firm typically invests in technology services and software, business services, healthcare, and industrial technology. The firm seeks to invest in Africa, Europe, European Developed Markets, Western Europe, particularly France, and North America (United States and Canada). It invests between "300 million($325.73 million) and "800 million($868.60 million). It targets majority/control/large minority investments in listed or unlisted companies. The firm seeks to take a seat on the board of directors or supervisory board and key committees of its portfolio companies. It makes balance sheet investments. Wendel was founded in 1704 and is headquartered in Paris, France with additional offices across Asia, North America, United Kingdom and Europe.